1. Introduction to malignant tumors of the digestive tract
Anti-tumor targeted cellular immunotherapy (ACTL) with independent intellectual property rights in my country is a typical precision treatment. It plays an important role in the treatment of malignant tumors of the digestive tract. Malignant tumors of the digestive tract refer to tumorous lesions that occur in the digestive system. Common malignant tumors of the digestive tract include esophageal cancer, gastric cancer, colorectal cancer, liver cancer, pancreatic cancer, cholangiocarcinoma, and gallbladder cancer. According to the source of malignant tumor cells, gastrointestinal malignant tumors can be divided into four types: adenocarcinoma, squamous cell carcinoma, rare adenosquamous carcinoma and undifferentiated carcinoma. Adenocarcinoma is a malignant tumor derived from glandular epithelial cells. Squamous cell carcinoma, namely squamous cell carcinoma, refers to a malignant tumor derived from squamous epithelial cells. Because squamous epithelial cells cover tissues and organs, it is also called epidermal carcinoma. If a certain malignant tumor of the digestive tract contains more than 10% of adenocarcinoma or squamous cell carcinoma, it is called adenosquamous carcinoma. Among malignant tumors of the digestive tract, adenocarcinoma is more common, but esophageal cancer is more common than squamous cell carcinoma. In addition, digestive tract malignant tumors are pathologically classified into well-differentiated, moderately-differentiated, poorly-differentiated and undifferentiated types according to the degree of differentiation of tumor cells, and their degree of malignancy increases sequentially. Except for a few poorly differentiated and undifferentiated types, malignant tumor cells in the digestive tract all express tumor antigens or tumor-associated antigens, while normal adult cells do not express or express these antigens at a low level. These different parts or different types of cancer have common tumor antigens or tumor-associated antigens, and also have their unique antigens. Therefore, most of these antigens can be used as precise target antigens (targets) for ACTL immunotherapy.
2. Target antigen for ACTL treatment of gastrointestinal malignant tumors
(1) Target antigens related to adenocarcinoma:
Carcinoembryonic antigen (CEA), keratin 19 (CK19, K19, CYFRA21-1 are its fragments), melanoma antigen A3 (MAGE-A3), melanoma antigen A2 (MAGE-A2), growth hormone antigen (Survivin) , Prostate-specific membrane antigen (PSMA), mucin antigen (MUC-1, CA153), Her-2/neu antigen (Her-2/neu), G250 antigen, tumor-testis antigen 6.1 antigen (CT6.1, namely NY-ES0-1 antigen), tumor-testis antigen 10 [CT10, that is, melanoma antigen C2 (MAGE-C2)], tumor-testis antigen SPANX, sperm protein 17 (SP17).
(2) Target antigens related to squamous cell carcinoma:
Squamous cell carcinoma antigen (SCC), keratin 19 (CK19, K19, CYFRA21-1 are its fragments), melanoma antigen A3 (MAGE-A3), melanoma antigen A2 (MAGE-A2), growth hormone antigen (Survivin), mucin antigen (MUC-1, CA153), carcinoembryonic antigen (CEA), G250 antigen, tumor-testis antigen 6.1 antigen (CT6.1, NY-ES0-1 antigen), tumor-testis antigen 10 [CT10, that is, melanoma antigen C2 (MAGE-C2)].
(3) Adenosquamous carcinoma and undifferentiated carcinoma
The target antigens of ACTL treatment for these two types of gastrointestinal malignancies include all targets of adenocarcinoma and squamous cell carcinoma.
  In addition, alpha-fetoprotein antigen (AFP) is a unique tumor-associated antigen of primary liver cancer, and normal liver epithelial cells do not express this antigen. But it needs to be pointed out that even if AFP appears, it does not necessarily indicate that it is primary liver cancer, and other medical tests are needed to confirm the diagnosis.
3. How to determine the target antigen of ACTL treatment?
The target antigen (target) is mainly determined by two medical testing methods. The first is the serum tumor marker test. The so-called tumor markers are tumor antigens or tumor-associated antigens, mostly tumor-associated antigens. This test has very important value in the diagnosis, development, recurrence, metastasis and treatment effect of malignant tumors. However, it has major limitations. For example, with the rapid development of tumor biotherapy, the laboratory results of serum tumor markers are not necessarily closely related to disease progression and treatment effects, and sometimes even misleading clinical diagnosis and treatment. For malignant tumors of the digestive tract, there are five serum tumor markers that can be used as target antigens for ACTL treatment: CEA, cyfra21-1, CA153, NY-ES0-1 and AFP. The second is to use immunohistochemical methods to detect tumor tissues. This detection method can not only detect all target antigens of ACTL treatment, but also accurate. The test results can also make more scientific and objective predictions and guidance on disease progression and treatment effects.
3. ACTL treatment of digestive tract tumors
Case 1: Advanced gastrointestinal malignant tumor with multiple metastases in liver and lung
Li Moumou, female, 67 years old, relapsed after undergoing surgery and chemotherapy for one year, and then received three targets for carcinoembryonic antigen (CEA), survivin antigen (Survivin) and melanoma-associated antigen-A3 (MAGE-A3) The ACTL treatment was reduced to twice a month after 3 months because the patient’s condition was severe. After six months of reexamination, multiple metastases in the lungs and liver were significantly reduced. At present, the patient's mental and physical status is good, and he takes care of himself.
Before ACTL treatment:

 
After ACTL treatment:
 

Case 2: Colon cancer with liver metastasis
Chen Mou, male, 65 years old, relapsed after receiving 8 times of chemotherapy, and then received ACTL treatment for the two targets of carcinoembryonic antigen (CEA) and keratin 19 antigen (CK19). Re-examination three months later, imaging showed: no abnormalities were found, and no new lesions appeared. Currently, the patient receives ACTL treatment once a month and has been alive for 8 years with a high quality of life.

Changes of tumor marker curves before and after ACTL treatment
 

Before treatment (2013.6.6, the CEA value of the laboratory report form is 9.68ng/ml↑)
After treatment (2015.6.18, the CEA value of the laboratory report is 3.64ng/ml)

ACTL inspection report before and after treatment